After PharmaSwiss, Valeant adds Lithuania's Sanitas to CEE base for €314 million
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals of Canada is acquiring an 87% stake in Lithuania's largest pharmaceutical manufacturer, Sanitas, for €314 million in cash in addition to the assumption of a €50 million debt. With Sanitas revenues for 2010 at just under $100 million, the deal values the company at around 3-3.5 time sales.